Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 4/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 11/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.81 |
| ▸ | TET3 | O43151 | 1/20 | 0.81 |
| ▸ | BRD4 | O60885 | 1/20 | 0.81 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.81 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.81 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.81 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380126 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL29454794 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL31087946 | 0.91 | HDAC1 (0.83) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL4349158 | 0.91 | HDAC1 (0.83) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL30255503 | 0.91 | HDAC1 (0.83) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL4349156 | 0.91 | HDAC1 (0.83) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| SCHEMBL11892323 | 0.90 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| Hydrochloric Acid SCHEMBL19743942 | 0.90 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| Panobinostat SCHEMBL164801 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC4 | |
| Panobinostat SCHEMBL22773814 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117598-A2 | FORMULATIONS OF DEACETYLASE INHIBITORS | Novartis AG (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008086330-A2 | FORMULATIONS OF DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | claimed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-2032531-B1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197936-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
| US-20100286409-A1 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | HTR3E, HTR3A, HTR3C | HDAC1 1483/4885HDAC2 798/4885HDAC3 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.